Sorted By Test Name - Mayo Medical Laboratories

FHER
91518
associated with infectivity. In acute cases, HBsAg usually disappears 1 to 2 months following the onset of
symptoms. Persistence of HBsAg for more than 6 months indicates development of either a chronic
carrier state or chronic liver disease. Hepatitis B core antibody (anti-HBc) IgM can be detected in serum
shortly after the onset of symptoms and is usually present up to 6 months. Anti-HBc IgM may be the only
serologic marker of a recent HBV infection and is detectable following the disappearance of HBsAg and
prior to the appearance of hepatitis Bs antibody (anti-HBs) (ie, core window period). Hepatitis C virus
(HCV) infection Anti-HCV is usually not detectable during the early months of infection with HCV. A
negative chemiluminescence immunoassay (CIA) antibody test result does not exclude the possibility of
exposure to or infection with HCV. Negative results in individuals with prior exposure to HVC may be
due to antibody levels below the limit of detection of this assay or lack of reactivity to the HCV antigens
used in this assay. Patients with recent infections with HCV may have false-negative results due to the
time required for seroconversion (an average of 8 to 9 weeks). If HCV infection is suspected, qualitative
HCV RNA testing is recommended. See Advances in the Laboratory Diagnosis of Hepatitis C (2002) in
Publications. Also see HBV Infection-Diagnostic Approach and Management Algorithm, Recommended
Approach to the Diagnosis and Monitoring of Patients with Hepatitis C Virus, and Viral Hepatitis
Serologic Profile in Special Instructions. A positive CIA screen result suggests the presence of anti-HCV
as a result of past or present HCV infection.
Reference Values:
HEPATITIS A ANTIBODY, IgG & IgM
Negative
HEPATITIS B SURFACE ANTIGEN
Negative
HEPATITIS B SURFACE ANTIBODY
Unvaccinated: negative
Vaccinated: positive
HEPATITIS B SURFACE ANTIBODY, QUANTITATIVE
Unvaccinated: or =12.0
HEPATITIS B CORE TOTAL
Negative
HEPATITIS C VIRUS ANTIBODY SCREEN
Negative
Clinical References: 1. Ergun GA, Miskovitz PF: Viral hepatitis: the new ABC's. Postgrad Med
1990 October;88(5):69-76 2. Sherlock S: Hepatitis B: the disease. Vaccine 1990;8 Suppl:S6-S9 3. Lemon
SM: Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin Chem 1997 August;43:(8 pt
2)1494-1499 4. Ciocca M: Clinical course and consequences of hepatitis A infection. Vaccine 2000;18
Suppl 1: S71-74 5. Choo QL, Weiner AJ, Overby LR, et al: Hepatitis C virus: the major causative agent
of viral non-A, non-B hepatitis. Brit Med Bull 1990 April;46(2):423-441
HER-2/neu, Quantitative, ELISA
Reference Values:
Reference Range: 0.0 - 15.0 ng/mL
Test Performed By: LabCorp Burlington
1447 York Court
Burlington, NC 27215-2230
Clinical References: Fehm T, Malmonis P, Weltz S, et al., Influence of circulating c-erb-2 serum
protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 909